Non-Hodgkin’s Lymphoma

  • David J. Wolf


Of the approximately 30,000 new patients diagnosed to have lymphoma in the United States during 1980, approximately one-fourth had Hodgkin’s disease. The remaining three-fourths were diagnosed to have a variety of different types of lymphoma, collectively categorized as non-Hodgkin’s lymphoma. The average age of these 22,500 people was 42 years. The incidence of non-Hodgkin’s lymphoma in the United States is increasing annually. The age distribution shows a steady rise from adolescence through the ninth decade of life. Males are affected approximately 1.5 times more often than females.


Chronic Lymphocytic Leukemia Malignant Lymphoma Complete Remission Rate Bone Marrow Involvement Combine Modality Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aisenberg AC and Bloch KJ: Immunoglobulins on the surface of neoplastic lymphocytes. N Engl J Med 287: 272–276, 1972PubMedCrossRefGoogle Scholar
  2. 1a.
    Anderson T, Bender RA, et al: Combination chemotherapy in non-Hodgkin’s lymphoma: Results of long term followup. Cancer Treat Rep 61: 1057–1066, 1977PubMedGoogle Scholar
  3. 2.
    Bagley C, DeVita VT, et al: Intensive cyclic che motherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76: 227–234, 1972PubMedGoogle Scholar
  4. 2a.
    Berard CW, Gallo RC, Jaffee ES, et al: Current concepts of leukemia and lymphoma: Etiology, pathogenesis and therapy. Ann Int Med 85: 351–366, 1976Google Scholar
  5. 3.
    Bisaccia EP, Grever MR, et a1: 2’ Deoxycoformycin-induced remission in advanced cutaneous T-cell lymphoma (abstract). Proc Am Soc Clin Oncol 1: 158, 1982Google Scholar
  6. 4.
    Bonadonna G, DeLena M, et al: Combination usage of Adriamycin in malignant lymphomas. Cancer Chemother Rep III 6: 381–388, 1975Google Scholar
  7. 5.
    Bonadonna G, Lattuada A, et al: Combined radiotherapy-chemotherapy in localized non-Hodgkin’s lymphoma, in Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer, ( ed 2 ). New York, Grune & Stratton, 1979, pp 145–153Google Scholar
  8. 5a.
    Brouet JC, Preud’homme, JL, Flandrin G, Chelloul N and Seligmann M: Membrane markers in “histiocytic” lymphomas (reticulum cell sarcoma). J Natl Cancer Inst 56: 631–633, 1976PubMedGoogle Scholar
  9. 6.
    Bush RS, Gospodarowicz M, et al: Radiation therapy of localized non-Hodgkin’s lymphoma. Cancer Treat Rep 61: 1129–1136, 1977PubMedGoogle Scholar
  10. 7.
    Chabner B, Johnson RB, et al: Sequential non-surgical and surgical staging of non-Hodgkin’s lymphoma. Ann Intern Med 85: 149–154, 1976PubMedGoogle Scholar
  11. 8.
    Chabner B, Fisher RI, et al: Staging of non-Hodgkin’s lymphoma. Semin Onco17(3):285–291, 1980Google Scholar
  12. 9.
    Cutterman JU, Yap Y, et al: Leukocyte interferoninduced tumor regression in human metastatic breast cancer, multiple lyeloma, and malignant lymphoma. Ann Intern Med 93: 399–406, 1980Google Scholar
  13. 10.
    DeVita VT, Canellos GP, et al: Advanced diffuse histiocytic lymphoma,.a potentially curable disease. Results with combination chemotherapy. Lancet 1: 248–250, 1975PubMedCrossRefGoogle Scholar
  14. 11.
    Dick FR, Fortuny I, et al: HL-A and lymphoid tumors. Cancer Res 32: 2608–2611, 1972PubMedGoogle Scholar
  15. 12.
    Ezdinli EZ, Costello WG, et al: Nodular mixed lymphocytic-histiocytic lymphoma. Response and survical. Cancer 45: 261–267, 1980PubMedCrossRefGoogle Scholar
  16. 13.
    Fisher RI, Kubota TT, et al: Regression of a T-cell lymphoma after administration of antithymocyte globulin. Ann Intern Med 88: 799–800, 1978PubMedGoogle Scholar
  17. 14.
    Fisher RI, DeVita VT, et al: Pro MACE-MOPP combination chemotherapy: Treatment of diffuse lymphomas (abstract). Proc Am Soc Clin Oncol 21: 468, 1980Google Scholar
  18. 15.
    Fisher RI, Hubbard S, et al: Factors predicting long term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 58: 45–51, 1981PubMedGoogle Scholar
  19. 15a.
    Frizzera G, Moran EM, Rappaport H: Angioblastic lymphadenopathy: Diagnosis and clinical course. AM J Med 59: 803–819, 1975PubMedCrossRefGoogle Scholar
  20. 16.
    Gallo RC, Kahpnanan UP, et al: Antibodies in human sera reactive against an internal structural protein of human T-cell lympoma virus. Nature 294 (5838): 271–273, 1981PubMedCrossRefGoogle Scholar
  21. 17.
    Glatstein E, Donaldson SS, et al: Combined modality therapy in malignant lymphomas. Cancer Treat Rep 61: 1199–1207, 1977Google Scholar
  22. 18.
    Hyman G, Sommers S: The development of Hodgkin’s disease and other lymphomas during anticonvulsant therapy. Blood 28: 416–427, 1966PubMedGoogle Scholar
  23. 18a.
    Jaffe ES, Shevach EJ, Sussman EH, et al: Membrane receptor sites for the identification of lymphoreticular cells in benign and malignant conditions. Brit J Cancer 31 (II): 107, 1975Google Scholar
  24. 19.
    Johnson RE: Management of generalized malignant lymphoma with “systemic” radiotherapy. Br J Cancer 31 (II): 450, 1978Google Scholar
  25. 20.
    Johnson RE, O’Conor GT: Primary management of advanced lymphosarcoma with radiotherapy. Cancer 25: 787–791, 1970PubMedCrossRefGoogle Scholar
  26. 21.
    Jones R, Hubbard SM: Histologic conversions in non-Hodgkin’s lymphoma. Clin Res 26: 437A, 1978Google Scholar
  27. 22.
    Jones SE, Rosenberg SA, et al: Non-Hodgkin’s lymphoma II: Single agent chemotherapy. Cancer 30: 31–39, 1972PubMedCrossRefGoogle Scholar
  28. 23.
    Jones SE, Fuks Z, et al: Non-Hodgkin’s lymphomas. V. Results of radiotherapy. Cancer 32: 682–691, 1973PubMedCrossRefGoogle Scholar
  29. 24.
    Kaplan HS, Goodenow RS, et al: Biology and virology of the human malignant lymphomas. Cancer 43: 1–24, 1979PubMedCrossRefGoogle Scholar
  30. 25.
    Kassan JS, Thomas TL, et al: Increased risk of lymphoma in Sicca syndrome. Ann Intern Med 89: 888–892, 1978PubMedGoogle Scholar
  31. 26.
    Kuhn JG, Knight WA, et al: Methyl-GAG in the management of non-Hodgkin’s lymphoma (abstract). Proc Am Soc Clin Oncol 1: 163, 1982Google Scholar
  32. 27.
    Lawrence J, Coleman M, et al: Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 94: 190–195, 1982Google Scholar
  33. 28.
    Liang W, Hopper JE: Karyotypic abnormalities in patients with multiple myeloma. Cancer 44: 630–644, 1979PubMedCrossRefGoogle Scholar
  34. 29.
    Luce JK, Gamble JT, et al: Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma. Cancer 28: 306–312, 1971PubMedCrossRefGoogle Scholar
  35. 30.
    Matas AJ, Hertel BF, et al: Post-transplant malignant lymphoma. Am J Med 61: 716–720, 1976PubMedCrossRefGoogle Scholar
  36. 31.
    McKelvey EM, Wilson HE, et al: Hydroxydaunomycin combination chemotherapy in malignant lymphoma: Cancer 38: 1484–1492, 1976Google Scholar
  37. 32.
    Miller DG: The association of immune disease and malignant lymphoma. Ann Intern Med 66: 507–521, 1967PubMedGoogle Scholar
  38. 33.
    Miller RA, Maloney DG, et al: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 308: 517–522, 1982CrossRefGoogle Scholar
  39. 34.
    Miller RW: Delayed radiation effects in atomic bomb survivors. Science 166: 569–574, 1969PubMedCrossRefGoogle Scholar
  40. 35.
    Miller TP, Jones SE: Chemotherapy of localized histiocytic lymphoma. Lancet 1: 358–360, 1979PubMedCrossRefGoogle Scholar
  41. 36.
    Newall J, Friedman M: Reticulum cell sarcoma. II. Radiation dosage for each type. Radiology 94: 643–647, 1970PubMedGoogle Scholar
  42. 37.
    Newcomer LN, Cadman BC, et al: Randomized study comparing ACOMLA with CHOP-B in the treatment of DHL. Cancer Treat Rep 66: 1279–1284, 1982PubMedGoogle Scholar
  43. 38.
    Nissen NI, Pajak T, et al: Overview of four clinical studies of chemotherapy for stage III and IV nonHodgkin’s lymphomas. Cancer Treat Rep 61: 1097–1107, 1977PubMedGoogle Scholar
  44. 39.
    Penn I: The incidence of malignancies in transplant recipients. Transplant Proc 7: 323–326, 1975PubMedGoogle Scholar
  45. 40.
    Portlock CS: Management of the indolent non-Hodgkin’s, lymphomas. Semin Oncol 7: 292–301, 1980PubMedGoogle Scholar
  46. 41.
    Reedman BM, Klein G: Cellular localization of EBV in lymphoblastoid cell lines. Int J Cancer 11: 499–520, 1973PubMedCrossRefGoogle Scholar
  47. 42.
    Ritz J, Nadler LM, et al: Expression of CALLA by lymphomas of B-cell and T-cell lineage. Blood 58: 648–652, 1981PubMedGoogle Scholar
  48. 43.
    Rowley JD, Fukuhara S: Chromosome studies in non-Hodgkin’s lymphomas. Semin Oncol 7: 255–266, 1980PubMedGoogle Scholar
  49. 44.
    Schein PS, DeVita VT, et al: BACOP combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med’ 85: 417–422, 1976Google Scholar
  50. 45.
    Skarin AT, Rosenthal DS, et al Combination chemotherapy of advanced non-Hodgkin’s lymphoma with BACOP. Blood 49: 759–770, 1977PubMedGoogle Scholar
  51. 46.
    Skarin A, Canellos GP, et al: Therapy of diffuse histiocytic and undifferentiated lymphoma with M-BACOD (abstract). Proc Am Soc Clip Oncol 21: 463, 1980Google Scholar
  52. 47.
    Sweet DL, Golomb HM, Kinzie J, et al: Survival in localized diffuse hystiocytic lymphoma (DHL). (abstract) Proc Am Soc Clin Onco121:465, 1980Google Scholar
  53. 48.
    Sweet DL, Golomb HM: The treatment of histiocytic lymphoma. Semin Oncol 7: 302–09, 1980PubMedGoogle Scholar
  54. 49.
    Sweet DL, Golomb HM, et al: COMLA combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 92: 785–790, 1980PubMedGoogle Scholar
  55. 50.
    Tirelli U, Carbone A, et al: VM 26 in non-Hodgkin’s lymphoma (abstract). Proc Am Soc Clin Oncol 1: 163, 1982Google Scholar
  56. 51.
    Turner DA, Fordam EW, et al: Gallium-67 imaging in the management of Hodgkin’s disease and other malignant lymphomas. Semin Nucl Med 8: 205–218, 1978PubMedCrossRefGoogle Scholar
  57. 52.
    Uchiyama T, Yodoi J, et al: Adult T-cell leukemia: Clinical and hematological features of 16 cases. Blood 50: 481–492, 1977PubMedGoogle Scholar
  58. 53.
    Uchiyama T, Sagawa K, et al: Effect of adult Tcell leukemia cells on pokeweed mitogen-induced normal B-cell differentiation. Clin Immunol Immunopathol 10: 24–34, 1978PubMedCrossRefGoogle Scholar
  59. 54.
    Van der Maaten MJ, Miller JM, Booth AD: Replicating type-C virus particles in monolayer cell cultures from cattle with lymphosarcoma. J Natl Cancer Inst 52: 491–497, 1974Google Scholar
  60. 55.
    Verones U, Misumeici R, et al: The value of staging laparotomy in non-Hodgkin’s lymphomas. Cancer 33: 446–469, 1974CrossRefGoogle Scholar
  61. 56.
    Warrell RP, Coonley CJ, et al: Clinical evaluation of gallium nitrate by 7-day continuous infusion in advanced malignant lymphoma (abstract). Proc Am Soc Clin Oncol 1: 160, 1982Google Scholar
  62. 57.
    Young RC, Johnson RE, et al: Advanced lymphocytic lymphoma-Randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep 61: 1153–1159, 1977PubMedGoogle Scholar
  63. 58.
    Young RC, Howser DM, et al: Central nervous system complications of non-Hodgkin’s lymphoma. Am J Med 66: 435–443, 1979PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1984

Authors and Affiliations

  • David J. Wolf

There are no affiliations available

Personalised recommendations